This ACI conference is an event which assists both brand name and generic pharmaceutical companies make sense of changing industry dynamics precipitated by the patent cliff and other factors such as patent reform, regulatory shifts and recent and pending case law. This conference sets the standards for Paragraph IV litigation and serves as an annual meeting place for the “who’s who” of pharmaceutical patent litigation. Goodwin Procter partner Elizabeth Holland will present on the panel, "Questions of Personal and General Jurisdiction in A Paragraph IV Case: Exploring Daimler’s Applicability in a Hatch Waxman Scenario" during which the panelists will examine AstraZeneca AB v. Mylan Pharmaceuticals, Inc. within the context of Daimler AG v. Bauman.
Speaking Engagements April 27, 2015 - April 28, 2015
New York, NY